<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56645">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02368691</url>
  </required_header>
  <id_info>
    <org_study_id>G200901</org_study_id>
    <nct_id>NCT02368691</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)</brief_title>
  <official_title>A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GTx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GTx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if GTx-024 is effective and safe in the treatment
      of patients with advanced, androgen receptor positive triple negative breast cancer (AR+
      TNBC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical benefit rate, in centrally confirmed AR+ subjects</measure>
    <time_frame>Sixteen (16) weeks</time_frame>
    <description>To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1 in subjects with centrally confirmed AR+ status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate, in full analysis set</measure>
    <time_frame>Sixteen (16) weeks</time_frame>
    <description>To estimate the clinical benefit rate in all subjects who receive at least one dose of study medication (full analysis set), regardless of central confirmation of AR status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>Twenty-four (24) weeks</time_frame>
    <description>To estimate the proportion of subjects who achieve clinical benefit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Twenty-four (24) weeks</time_frame>
    <description>To estimate the objective response rate (defined as complete response or partial response) according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response</measure>
    <time_frame>From treatment initiation to end of treatment</time_frame>
    <description>To assess best overall response as measured by RECIST 1.1 from the start of study treatment until the end of treatment taking into account any requirement for confirmation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From treatment initiation to tumor progression or death</time_frame>
    <description>To assess progression free survival defined as the time elapsed between initiation of treatment and tumor progression as measured by RECIST 1.1 or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-progression</measure>
    <time_frame>From treatment initiation to tumor progression or death</time_frame>
    <description>To assess time to progression defined as time elapsed between treatment initiation and tumor progression as measured by RECIST 1.1 or death due to disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>From time of documented tumor response to tumor progression or death</time_frame>
    <description>To assess the duration of response defined as the time from documentation of tumor response to disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Sixteen (16) weeks</time_frame>
    <description>To estimate the objective response rate (defined as complete response or partial response) according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to twenty-four (24) months</time_frame>
    <description>To estimate overall survival defined as the time from treatment initiation until death or date of last follow up to a maximum of 24 months post treatment initiation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Up to twelve (12) months</time_frame>
    <description>To describe the safety profile in subjects with TNBC and centrally confirmed AR+ as well as in all subjects enrolled and treated.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic assessment</measure>
    <time_frame>Up to twelve (12) months</time_frame>
    <description>To describe the plasma concentrations of GTx-024 and GTx-024 glucuronide at each of the assessed time points.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>GTx-024</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GTx-024 capsules, 18 mg PO once-daily for up to 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GTx-024</intervention_name>
    <description>GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg</description>
    <arm_group_label>GTx-024</arm_group_label>
    <other_name>Enobosarm</other_name>
    <other_name>Ostarine</other_name>
    <other_name>S-22</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able and willing to give voluntary, written and signed, informed consent

          -  Women ≥ 18 years of age

          -  Women with TNBC who have received at least one but no more than two prior
             chemotherapy regimens for TNBC

          -  Confirmation of AR+ (defined as ≥ 10% nuclear AR staining by immunohistochemistry
             [IHC]) TNBC in either the primary or metastatic lesion, assessed during the screening
             period by a local laboratory or by medical history

          -  TNBC confirmed by medical history as: human epidermal growth factor receptor 2
             [HER2]-negative (confirmed by IHC 0, 1+ regardless of fluorescence in situ
             hybridization [FISH] ratio; IHC 2+ with FISH ratio lower than 2.0 or HER2 gene copy
             less than 6.0; FISH ratio of 0, indicating gene deletion, when positive and negative
             in situ hybridization [ISH] controls are present); estrogen receptor (ER) negative
             (confirmed as ER expression less than or equal to 1% positive tumor nuclei);
             progesterone receptor negative (confirmed as progesterone receptor expression less
             than or equal to 1% positive tumor nuclei)

          -  Availability of paraffin embedded or formalin fixed tumor tissue; OR, a minimum of 10
             and up to 20 slides of archived tumor tissue for central laboratory confirmation of
             AR status and molecular subtyping. Metastatic tumor tissue is preferred when possible

          -  Subjects must have either measurable disease or bone-only non-measurable disease,
             evaluable according to RECIST 1.1

          -  Subjects with bone metastases should be treated with intravenous bisphosphonates or
             subcutaneous denosumab (or investigator preferred standard of care) prior to and
             during the trial, unless there is a contraindication or subject intolerance to these
             therapies

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at the time of
             screening and enrollment

          -  Negative pregnancy test in women of childbearing potential (premenopausal or less
             than 12 months of amenorrhea post-menopause, and who have not undergone surgical
             sterilization), no more than 7 days before the first dose of study treatment

          -  For women of childbearing potential who are sexually active, agreement to use a
             highly effective, non-hormonal form of contraception during and for at least 6 months
             after completion of study treatment; OR, a fertile male partner willing and able to
             use effective non-hormonal of contraception (barrier method of contraception in
             conjunction with spermicidal jelly, or surgical sterilization) during and for at
             least 6 months after completion of study treatment

          -  Adequate organ function as shown by:

               -  Absolute neutrophil count ≥ 1,000 cells/mm3

               -  Platelet count ≥ 100,000 cells/mm3

               -  Hemoglobin ≥ 9 g/dL

               -  Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5
                  Upper Limit of the Normal range (ULN) (or ≤ 5 if hepatic metastases are present)

               -  Total serum bilirubin ≤ 2.0 × ULN (unless the subject has documented Gilbert
                  Syndrome)

               -  Alkaline phosphatase levels ≤ 2.5 × ULN (≤ 5 × ULN in subjects with liver
                  metastasis)

               -  Serum creatinine &lt; 2.0 mg/dL or 177 μmol/L

               -  International normalized ratio (INR), activated partial thromboplastin time
                  (aPTT), or partial thromboplastin time (PTT) &lt; 1.5 × ULN (unless on
                  anticoagulant treatment at screening)

          -  Able to swallow capsules

          -  Any toxicity from prior chemotherapy has resolved or Grade 1 (NCI-CTCAE, Version 4.0)

        Exclusion Criteria:

          -  Life expectancy &lt; 4 months;

          -  Subjects with radiographic evidence of central nervous system (CNS) metastases as
             assessed by computerized tomography (CT) or magnetic resonance imaging (MRI) that are
             not well controlled (symptomatic or requiring control with continuous corticosteroid
             therapy [e.g., dexamethasone]). Note: Subjects with CNS metastases are permitted to
             participate in the study if the CNS metastases are medically well controlled prior to
             screening (as assessed by the Investigator) after receiving local therapy
             (irradiation, surgery, etc.)

          -  Radiotherapy within 14 days prior to first dose of study treatment

          -  Have, in the judgment of the Investigator, a clinically significant concurrent
             illness or psychological, familial, sociological, geographical, or other concomitant
             condition that would not permit adequate follow-up and compliance with the study
             protocol

          -  Positive hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection at
             screening

          -  Positive human immunodeficiency virus (HIV) infection at screening

          -  Prior treatment with any anti-androgens, including but not limited to, enzalutamide
             and bicalutamide

          -  Major surgery within 28 days of the first dose of study treatment

          -  Be currently taking or have previously taken testosterone, methyltestosterone,
             oxandrolone (Oxandrin®), oxymetholone, danazol, fluoxymesterone (Halotestin®),
             testosterone-like agents (such as dehydroepiandrosterone, androstenedione, and other
             androgenic compounds, including herbals), or anti-androgens

          -  Treatment with any of the following hormone replacement therapies, unless
             discontinued at least 14 days prior to the first dose of study treatment:

               -  Estrogens

               -  Megesterol acetate

          -  Treatment with any investigational agent within 28 days before the first dose of
             study treatment

          -  Another active cancer (excluding adequately treated basal cell carcinoma or cervical
             intraepithelial neoplasia [CIN]/cervical carcinoma in situ or melanoma in situ).
             Prior history of other cancer is allowed as long as there is no active disease within
             the prior 5 years

          -  Subject has a concomitant medical condition that precludes adequate study treatment
             compliance or assessment, or increases subject risk, in the opinion of the
             Investigator, such as but not limited to:

               -  Myocardial infarction or arterial thromboembolic events within 6 months prior to
                  baseline or severe or unstable angina, New York Heart Association (NYHA) Class
                  III or IV disease, or a QTcB (corrected according to Bazett's formula) interval
                  &gt; 470 msec; serious uncontrolled cardiac arrhythmia grade II or higher according
                  to NYHA; uncontrolled hypertension (systolic &gt; 150 and/or diastolic &gt; 100 mm Hg)

               -  Acute and chronic active infectious disorders and non-malignant medical
                  illnesses that are uncontrolled or whose control may be jeopardized by the
                  complications of this study therapy

               -  Impairment of gastrointestinal function or gastrointestinal disease that may
                  significantly alter the absorption of study drugs (e.g., ulcerative disease,
                  uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)

          -  Current treatment with intravenous bisphosphonate or denosumab with elevated serum
             calcium corrected for albumin or ionized calcium levels outside institutional normal
             limits at screening

          -  History of non-compliance to medical regimens

          -  Subjects unwilling to or unable to comply with the protocol procedures as assessed by
             the Investigator

          -  Concurrent participation in another therapeutic clinical trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hope S Rugo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mayzie Johnston, PharmD</last_name>
    <phone>(901) 523-9700</phone>
    <email>mjohnston@gtxinc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Georgi, RN</last_name>
      <phone>954-267-7748</phone>
      <email>eileen.georgi@holy-cross.com</email>
    </contact>
    <investigator>
      <last_name>Zdenka E Segota, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lakeland Regional Health Care/Cancer Center</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>863-904-1900</phone>
    </contact>
    <investigator>
      <last_name>Madhavi L Venigalla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Liendo</last_name>
      <phone>305-243-0864</phone>
      <email>mx11108@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Charles L Vogel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cortlin Croft</last_name>
      <phone>813-745-7559</phone>
      <email>Cortlin.Croft@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Martine Extermann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent Frontier Cancer Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>406-238-6962</phone>
    </contact>
    <investigator>
      <last_name>Patrick W Cobb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The West Clinic, PC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>901-683-0055</phone>
      <phone_ext>1141</phone_ext>
    </contact>
    <investigator>
      <last_name>Gregory Vidal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>US Oncology / Texas Oncology, P.A.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Lopez</last_name>
      <phone>713-467-1722</phone>
      <email>ruth.lopez@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Gail Cooksey</last_name>
      <phone>713-467-1722</phone>
      <email>gail.cooksey@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Frankie Ann Holmes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 30, 2016</lastchanged_date>
  <firstreceived_date>February 10, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
